Drug intelligence / Profile preview

OV-151

Development stage: Preclinical
Lead developer: Vivere Oncotherapies
Modality: Gene Silencing → Gene Therapies, Oncolytic Viruses → Oncolytic Therapeutics, Gene Editing → Gene Therapies, Gene Addition/Replacement → Gene Therapies

Overview

OV-151 is an evolved oncolytic virotherapy product being developed by Vivere Oncotherapies, a UC Berkeley spin-out. It consists of a viral vector engineered to selectively replicate within tumor cells and deliver genetic cargo designed to mediate multi-antigen targeting of immune cells to the tumor microenvironment. This approach aims to combine the therapeutic mechanisms of CAR-T cell therapy and checkpoint inhibitors to treat 'cold' tumors, with a primary focus on colorectal cancer. Currently in the preclinical stage, the program is advancing toward IND-enabling studies, supported by a 2025 NIH STTR Phase I SBIR award.

Beyond the preview

Go deeper on OV-151.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OV-151.

Explore the full profile